Eosinophilic Esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus caused by an accumulation of eosinophils leading to a difficulty in swallowing food with the potential for dangerous food impaction. Topical steroids and proton pump inhibitors are the mainstays of clinical management for EoE, however the indication has no official therapy approvals by FDA. EoE has an active pipeline that will further drive off-label use until novel therapies with unique MOAs reach the market. As the EoE current treatment landscape continues to evolve, this report offers insights from real-world claims data into prescribing trends in EoE to help new players to better understand current treatment practices in EoE and help define the market niche for their emerging product.
Real World data
Longitudinal patient-level claims data analysis
Key Drugs Covered
Fluticasone, budesonide, ciclesonide, prednisone, dexlansoprazole, omeprazole, esomeprazole, lansoprazole, rabeprazole, and pantoprazole
Key Analysis provided
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.